Obesity and “functional hypogonadism”—mechanisms and management: commentary on EJE-22-1110 “leflutrozole in male obesity-associated hypogonadotropic hypogonadism: Ph 2b double-blind RCT”
European Journal of Endocrinology · 2023
DOI: 10.1093/ejendo/lvad100 ↗Kurz gefasst
Editorial in der Zeitschrift European Journal of Endocrinology, 2023. Verfasst von Warrick J Inder und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, Princess Alexandra Hospital, 199 Ipswich Rd, Woolloongabba, QLD 4102, Australia. Hauptthemen laut MEDLINE: Hypogonadism. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
In their paper published in the European Journal of Endocrinology, Jones et al. have undertaken a double-blind randomized controlled trial of weekly leflutrozole—an aromatase inhibitor (AI), for the treatment of obesity-associated “functional hypogonadism”. To briefly summarize their findings, they showed a dose-dependent increase in serum testosterone, luteneising hormone (LH), and follicle stimulating hormone, along with improved semen volume and motile sperm count in the subset of participants who provided semen samples. Symptoms of sexual dysfunction were not alleviated, nor was there any improvement in fatigue or general health. Adverse effects were observed, particularly in the highest weekly dose of 1.0 mg, most commonly elevated haematocrit, hypertension, headache, and increased prostate specific antigen. Bone mineral density fell significantly at the lumbar spine across all doses compared to placebo. Classical male hypogonadism is caused by organic testicular or hypothalamic–pituitary pathology and designated primary or secondary, respectively. Obesity-associated “functional hypogonadism” is a somewhat controversial entity conceptualized as a form of secondary hypogonadism. However, dynamic function testing with gonadotrophin-releasing hormone (GnRH) and human chorionic gonadotrophin (hCG) reveals normal pituitary and testicular responsiveness, while blockade of oestrogen negative feedback using the selective oestrogen receptor modulator (SERM) clomifene induces a robust increase in LH and testosterone.1 In the setting of obesity with body mass index (BMI) 30-40 kg/m2, total testosterone and sex hormone binding globulin (SHBG) are both low but free testosterone concentrations are maintained within the normal range (a condition referred to as pseudo-hypogonadism).2 Once the BMI increases above 40 kg/m2, total and free testosterone are both reduced and LH pulse amplitudes fall. However, whether this biochemical abnormality is associated with clinical consequences remains uncertain, as carefully conducted studies generally report a paucity of signs of androgen deficiency in otherwise healthy obese men, even if BMI exceeds 40 kg/m2; for review, see the work of Grossmann.1 The absence of any irreversible defect in the hypothalamic–pituitary–testicular (HPT) axis is confirmed by the observation that there is improvement and indeed normalization of serum testosterone in the setting of significant weight loss.3
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diabetes and Endocrinology, Princess Alexandra Hospital, 199 Ipswich Rd, Woolloongabba, QLD 4102, Australia.
- PA-Southside Clinical Unit Medical School, The University of Queensland, 199 Ipswich Rd, Woolloongabba, QLD 4102, Australia.
- Department of Medicine, Austin Health University of Melbourne, 145 Studley Road, Heidelberg, VIC 3084, Australia.
- Department of Endocrinology, Austin Health, 145 Studley Road, Heidelberg, VIC 3084, Australia.
ORCID-Profile: Warrick J Inder, Mathis Grossmann
Zitieren
APA
Inder, W. J., & Grossmann, M. (2023). Obesity and “functional hypogonadism”—mechanisms and management: commentary on EJE-22-1110 “leflutrozole in male obesity-associated hypogonadotropic hypogonadism: Ph 2b double-blind RCT”. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvad100
Vancouver
Inder WJ, Grossmann M. Obesity and “functional hypogonadism”—mechanisms and management: commentary on EJE-22-1110 “leflutrozole in male obesity-associated hypogonadotropic hypogonadism: Ph 2b double-blind RCT”. European Journal of Endocrinology. 2023. doi:10.1093/ejendo/lvad100
BibTeX
@article{Inder2023,
author = {Inder, Warrick J and Grossmann, Mathis},
title = {Obesity and “functional hypogonadism”—mechanisms and management: commentary on EJE-22-1110 “leflutrozole in male obesity-associated hypogonadotropic hypogonadism: Ph 2b double-blind RCT”},
journal = {European Journal of Endocrinology},
year = {2023},
doi = {10.1093/ejendo/lvad100}
}
EUVIMED